A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)
Latest Information Update: 30 Nov 2023
At a glance
- Drugs TQ-B3525 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 24 Nov 2023 Status changed from recruiting to discontinued due to the R&D strategy change.
- 06 Jun 2021 Status changed from not yet recruiting to recruiting.
- 24 Mar 2021 New trial record